Cardio3 BioSciences (C3BS), a developer of regenerative and protective therapies, has received CE mark approval for its intra-myocardial C-Cath injection catheter.

The company said C-Cath injection catheter was designed to meet ease of use, safety and efficacy.

C-Cath injection catheter’s preclinical data from a head to head comparison trial showed threefold increase in retention of stem cells within the heart muscle, when compared to currently available injection catheter.

Cardio3-BioSciences CEO Christian Homsy said by utilizing C-Cath technology, the company has developed a injection catheter that meets the requirements of physicians and has the potential to deliver better outcomes for patients.

"This is a major step forward in addressing the patient needs for regenerative therapies for the heart and provides physicians with new treatment options," Homsy added.